NHS England

Clinical Commissioning Policy: Renal denervation for resistant hypertension

Reference: NHS England: 16004/P

NHS England INFORMATION READER BOX		
Directorate		
Medical	Operations and Information	**Specialised Commissioning**
Nursing	Trans. & Corp. Ops.	Commissioning Strategy
Finance		

Publications Gateway Reference:	**05527s**
Document Purpose	Policy
Document Name	Clinical Commissioning Policy 16004/P
Author	Specialised Commissioning Team
Publication Date	13 July 2016
Target Audience	CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs
Additional Circulation List	
Description	Not Routinely Commissioned - NHS England will not routinely commission this specialised treatment in accordance with the criteria described in this policy.
Cross Reference	This document is part of a suite of policies with Gateway Reference 05527s.
Superseded Docs (if applicable)	N/A
Action Required	N/A
Timing / Deadlines (if applicable)	**N/A**
Contact Details for further information	england.specialisedcommissioning@nhs.net

Document Status

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.

Clinical Commissioning Policy: Renal denervation for Resistant Hypertension

First published: July 2016

Prepared by NHS England Specialised Services Clinical Reference Group for Complex Invasive Cardiology

Published by NHS England, in electronic format only.

Contents

Policy Statement

NHS England will not routinely commission renal denervation for resistant hypertension for adults in accordance with the criteria outlined in this document.
In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement

Promoting equality and addressing health inequalities are at the heart of NHS England's values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary

About high blood pressure (hypertension)

High blood pressure is not something that you can usually feel or notice. The heart needs pressure in the blood vessels to pump blood around the body – to deliver energy and oxygen. However, if this pressure is too high, it puts too much strain on the arteries and heart. This can lead to serious conditions affecting the heart and other organs.

About the current treatment

There are several ways to reduce blood pressure. For most patients, changes in lifestyle such as eating less salt or losing weight are enough to manage the risks. However, for others, medicines may be needed.

‘Resistant’ hypertension is blood pressure that remains high despite treatment with three or more medicines. It is an especially dangerous long-term illness because it brings increased risk of:

- stroke
- heart attack
- heart failure
- kidney disease.

About the new treatment

In ‘renal denervation’ the nerves in the patient's kidneys are damaged on purpose. These nerves pass information between the kidney and the brain – and have a role in controlling blood pressure. Doctors and scientists are interested in renal denervation as a possible treatment for patients with resistant hypertension.

What we have decided

NHS England has carefully reviewed the evidence to treat resistant hypertension with renal denervation. We have concluded that there is not enough evidence to make the treatment available at this time.

1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission renal denervation.

Hypertension, also known as high blood pressure, is a chronic medical condition in which the blood pressure in the arteries is persistently elevated. This puts extra strain on the arteries and heart, which can lead to serious conditions such as heart attack, heart failure, kidney disease, stroke, or dementia.

There are several ways to reduce blood pressure. For many people, changes in lifestyle such as eating less salt or losing weight can be sufficient to reduce the risks. Some individuals however, will require medication with one or more antihypertensive medications.

There are a small number of people who will still not be able to reduce their blood pressure to normal levels (a "clinic" systolic blood pressure of <160 mm Hg). At the point where they have tried three or more of the conventional antihypertensive agents they will be diagnosed with resistant hypertension.

It is known that the renal nerves (sympathetic nerves) can be a main cause of hypertension when they become overactive. The renal denervation procedure inserts a device through the groin to deliver radiofrequency energy to deaden the nerves associated with the renal arteries. There is clinical interest as to whether renal denervation may be effective as a treatment option for individuals with drug-resistant hypertension.

2 Definitions

Resistant hypertension is defined as when an individual cannot control their blood pressure despite the use of at least three antihypertensive agents.

Renal denervation is a minimally invasive procedure during which a device is inserted through the groin to deliver radiofrequency energy to the nerves in the wall of the renal arteries; damaging (or ablating) these nerves may be a method to reduce blood pressure.

3 Aims and Objectives

This policy aims to define NHS England's commissioning position on renal denervation as part of the treatment pathway for adult patients with resistant hypertension.

The objective is to ensure evidence based commissioning in the use of renal denervation for the treatment of adults with resistant hypertension.

4 Epidemiology and Needs Assessment

The 2010 Health Survey for England estimated that the prevalence of hypertension in adults of 16 years or older was 31.5% in men and 29.0% in women (Department of Health 2011). Diagnosis is, however, recognised as being complicated by several factors, not least because high blood pressure often does not have any symptoms and can only be established through a blood pressure check. Added to this, for some individuals, having health concerns may, in itself, cause the blood pressure to increase prior to examination which can lead to a misleading result. When seeking to establish resistant hypertension, it is also difficult to clearly evidence that individuals are taking their antihypertensive medications correctly.

It is known that there are a number of risk factors that increase the risk of high blood pressure, including:

a) age (risk increases significantly for those over the age of 65)

b) obesity

c) familial history

d) among individuals of African or Caribbean descent

e) diet – excess salt, caffeine, alcohol and not enough fruit and vegetables

g) low levels of exercise

h) smoking

Post hoc analyses of large scale trials of antihypertensive medications plus retrospective cross sectional observational studies point to a prevalence of resistant hypertension of 10-20% of the general hypertensive population (Letters BMJ 2012).

Studies indicate that 5-10% of resistant hypertension patients have an underlying secondary cause for their elevated blood pressure—a prevalence significantly greater than that of the general hypertensive population (Rapid Response Letters BMJ 2012).

Patients with resistant hypertension are almost 50% more likely to experience an adverse cardiovascular event compared with patients with blood pressure controlled by three or fewer antihypertensive agents (Rapid Response BMJ 2012).

5 Evidence Base

NHS England has concluded that there is not sufficient evidence to support a proposal for the routine commissioning of renal denervation for resistant hypertension.

This evidence review has sought to address the following research questions:

Research question 1: Is renal denervation clinically effective in patients with resistant hypertension (RH)?

Research question 2: Is renal denervation cost effective in patients with resistant hypertension (RH)?

In summary, the current evidence base is inconclusive for the clinical effectiveness of renal denervation (RDN) over current standard of care treatments for resistant hypertension with the more recent randomised control trial and meta-analysis indicating nil to modest impact of RDN on lowering blood pressure.

Question 1. Is renal denervation clinically effective in patients with resistant hypertension?

Early studies from 2010 onwards suggested that renal denervation (RDN) was a more clinically effective method of treatment than standard of care pharmacological interventions for patients with resistant hypertension (RH) (Esler et al., 2011). Meta-

analyses based on such studies therefore found a significant effect in RH patients treated with RDN, which, added to the high levels of safety reported, resulted in general support for the use of this technology (Howard et al., 2013, Davis et al., 2013). More recently, Azizi et al., (2015) also showed a significant result in RDN patients against a control population that received stepped-care anti-hypertensive treatment).

The effectiveness of RDN was most recently challenged by the PRAGUE-15 trial (Rosa et al., 2015), which reported no significant benefits of RDN over an intensified pharmacological regimen including spironolactone. However, these RCTs were non-blinded, which made it difficult to ascertain the extent of the placebo effect (Jin et al., 2014). For this reason the outcomes from SYMPLICITY HTN-3, a blinded RCT with a control group that received a placebo procedure (angiogram in lieu of renal denervation), were much anticipated.

In 2014, the 6-month results from the SYMPLICITY HTN-3 trial were published (Bhatt et al., 2014), and it reported that RDN produced insignificant reductions in both office and ambulatory systolic blood pressure. This data, however, was not immediately conclusive. Howard et al. (2013) concluded that even if results from this blinded RCT were to report lower blood pressure reductions than expected, a significant clinical impact would still be felt as long as blood pressure drops were in the region of 10 - 16 mm Hg.

Recently, the 12-month ambulatory blood pressures from the SYMPLICITY HTN-3 trial were published (Bakris et al., 2015). Ambulatory blood pressures are regarded as a more accurate measure compared to office blood pressure due to elimination of the white coat effect and averaging over 24 hours. The 6-month and 12-month results together paint an inconclusive story. Interestingly, the blinded trial produced no significant difference from the placebo - the difference in systolic blood pressure (SBP) reduction at 12 months was −2.39 mm Hg, which would itself suggest that the RDN procedure is not clinically effective (Bhatt et al., 2014, Bakris et al., 2015). However, unlike previous trials, patients in the placebo group actually responded to the control (placebo) procedure, with systolic blood pressure (SBP) drops of −11.74±25.94 mm Hg in the sham control group at 6 months (Bhatt et al., 2014). This could be due to the Hawthorne effect, where patient medication adherence is

improved in both study arms (Kwok et al., 2014). Meanwhile, the RDN group registered an SBP drop of −14.13±23.93 mm Hg at 6 months (Bhatt et al., 2014) and 15.5 +/- 24.1 mm Hg at 12 months (Bakris et al., 2015). Although the differences were not significant between the RDN and placebo group the magnitude of the drop falls within the range that Howard et al. (2013) indicated would be clinically meaningful.

Siagian et al. (2014) stated that the limitations of SYMPLICITY HTN-3 trial included the regression-to-mean phenomenon, a lower baseline blood pressure than other studies in the past (159.1 mm Hg vs 180 mm Hg), and that there were no measurements taken to affirm the extent of the renal denervation and that the operators were inexperienced, although the authors of the study (Bhatt et al., 2014) claimed that operators who had operated five times on patients did not produce better blood pressure results in the last operation compared to the first.

Patients in the SYMPLICITY HTN-3 trial also consumed higher amounts of the antihypertensive medication spironolactone (Kwok et al., 2014), which acts mechanistically similar to RDN (Pancholy et al., 2014). Such vasodilators have been shown to be a predictor for non-response in renal denervation procedures (Siagian et al., 2014). In addition, no urine test was taken to verify patient medication adherence, and results from this trial are only strictly applicable to catheters using the same radiofrequency-based technology found in the Simplicity catheters manufactured by Medtronic, and may not be directly translatable for ultrasound ablation catheters such as PARADISE (ReCor Medical, Ronkoma, New York) due to the unipolar nature of the SYMPLICITY system, which makes it more technically difficult to ensure circumferential ablation compared to more modern multipolar systems (Kwok et al., 2014).

Fadl et al., 2015 have reported a high quality meta-analysis of the data from 7 recently published randomized controlled trials (SYMPLICITY HTN-2 SYMPLICITY HTN-3 OSLO RDN PRAGUE-15 DENERHTN SYMPLICITY-FLEX SYMPLICITY HTN-Japan) which provides conclusive evidence that RDN is effective in a carefully selected patient sub-populations (stage I–II hypertension, low risk factor profile and evidence of sympathetic overactivity). The BP-lowering effect of RDN on top of continued or optimized antihypertensive drug treatment is modest, averaging 4.9

mmHg systolic and 3.5 mmHg diastolic on office measurement, and 2.8 mmHg systolic and 1.5 mmHg diastolic on 24 h ambulatory monitoring in the short term.

The current evidence base therefore fails to provide conclusive evidence in favour of RDN's clinical effectiveness over current standard of care treatments for resistant hypertension.

Question 2. Is renal denervation cost effective in patients with resistant hypertension?

There is only one paper in the literature search that provided evidence for the cost effectiveness of renal denervation in the context of resistant hypertension. Gladwell et al., 2014 concluded that RDN resulted in a greater health benefit to the patient compared to standard of care pharmacological intervention alone, extending QALYs from 12.16 to 12.77. This added health benefit came at a cost of £4805 per QALY. However, Gladwell et al., 2014 published their findings in the same year as the publication of SYMPLICITY HTN-3 trial results but were not able to include these results in their economic model. Given the reported lack of clinical effectiveness in SYMPLICITY HTN-3 (Bhatt et al., 2014, Bakris et al., 2015), the cost effectiveness of this treatment is likely to impact on the cost-effectiveness analysis. An updated model including results from this blinded RCT is needed before the cost effectiveness of RDN for resistant hypertension can be accurately ascertained.

6 Documents which have informed this Policy

Hypertension in adults: diagnosis and management NICE guidelines [CG127] Published date: August 2011

Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension NICE interventional procedure guidance [IPG418] Published date: January 2012

Clinical Commissioning Policy Statement: Renal Denervation for Resistant Hypertension. April 2013. Reference: NHSCB/A09/PS/d

7 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.

References

Department of Health: Health Survey for England - 2010, Trend tables [NS]. Published date: 15 December 2011

Clinical Review Resistant hypertension BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7473 (Rapid response Published 20 November 2012)

Azizi, Michel; Sapoval, Marc; Gosse, Philippe; Monge, Matthieu; Bobrie, Guillaume; Delsart, Pascal; Midulla, Marco; Mounier-Véhier, Claire; Courand, Pierre-Yves; Lantelme, Pierre; Denolle, Thierry; Dourmap-Collas, Caroline; Trillaud, Hervé; Pereira, Helena; Plouin, Pierre-François; Chatellier, Gilles; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015;385 (9981):1957-1965.

Bakris et al., 2015Bakris, George L.; Townsend, Raymond R.; Liu, Minglei; Cohen, Sidney A.; D'Agostino, Ralph; Flack, John M.; Kandzari, David E.; Katzen, Barry T.; Leon, Martin B.; Mauri, Laura; Negoita, Manuela; O'Neill, William W.; Oparil, Suzanne; Rocha-Singh, Krishna; Bhatt, Deepak L.; SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J. Am. Coll. Cardiol. 2015;65(13):1314-1321.

Bhatt, Deepak L.; Kandzari, David E.; O'Neill, William W.; D'Agostino, Ralph; Flack, John M.; Katzen, Barry T.; Leon, Martin B.; Liu, Minglei; Mauri, Laura; Negoita, Manuela; Cohen, Sidney A.; Oparil, Suzanne; Rocha-Singh, Krishna; Townsend, Raymond R.; Bakris, George L.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370(15):1393-1401.

Davis, Mark I.; Filion, Kristian B.; Zhang, David; Eisenberg, Mark J.; Afilalo, Jonathan; Schiffrin, Ernesto L.; Joyal, Dominique. Effectiveness of renal denervation

therapy for resistant hypertension: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2013;62(3):231-241.

Esler, Murray D.; Böhm, Michael; Sievert, Horst; Rump, Christian L.; Schmieder, Roland E.; Krum, Henry; Mahfoud, Felix; Schlaich, Markus P.. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur. Heart J. 2014;35(26):1752-1759.

Fadl Elmula, Fadl Elmula M.; Jin, Yu; Yang, Wen-Yi; Thijs, Lutgarde; Lu, Yi-Chao; Larstorp, Anne C.; Persu, Alexandre; Sapoval, Marc; Rosa, Ján; Widimský, Petr; Jacobs, Lotte; Renkin, Jean; Petrák, Ondřej; Chatellier, Gilles; Shimada, Kazuyuki; Widimský, Jiři; Kario, Kazuomi; Azizi, Michel; Kjeldsen, Sverre E.; Staessen, Jan A.; European Network Coordinating Research On Renal Denervation (ENCOReD) Consortium. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24(5):263-274.

Gladwell, Daniel; Henry, Thea; Cook, Mark; Akehurst, Ron. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy 2014;12(6):611-622.

Howard, James P.; Nowbar, Alexandra N.; Francis, Darrel P.. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013;99(21):1579-1587.

Jin, Yu; Jacobs, Lotte; Baelen, Marie; Thijs, Lutgarde; Renkin, Jean; Hammer, Frank; Kefer, Joelle; Petit, Thibault; Verhamme, Peter; Janssens, Stefan; Sinnaeve, Peter; Lengelé, Jean-Philippe; Persu, Alexandre; Staessen, Jan A.; investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) investigators. Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press. 2014;23(3):138-146.

Kwok, Chun Shing; Loke, Yoon K.; Pradhan, Shiva; Keavney, Bernard; El-Omar, Magdi; Mamas, Mamas A.. Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis. Open Heart 2014;1(1):e000092

Pancholy, Samir B.; Shantha, Ghanshyam Palamaner Subash; Patel, Tejas M.; Sobotka, Paul A.; Kandzari, David E.. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am. J. Cardiol. 2014;114(6):856-861.

Rosa, Ján; Widimský, Petr; Toušek, Petr; Petrák, Ondřej; Čurila, Karol; Waldauf, Petr; Bednář, František; Zelinka, Tomáš; Holaj, Robert; Štrauch, Branislav; Šomlóová, Zuzana; Táborský, Miloš; Václavík, Jan; Kociánová, Eva; Branny, Marian; Nykl, Igor; Jiravský, Otakar; Widimský, Jiří. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015;65(2):407-413.

Siagian, Minarma; Ferly, Aldo; Irianti, Arinna; Kurniati, Arky; Low, Florence; Riza, Ras A. Effectiveness of renal denervation for treatment of resistant hypertension: an evidence-based case report. Acta Med Indones 2014;46(4):341-347.